Head of Data Management beats his personal best in the 2006 London Marathon

Posted:
28
April 2006

Adam Walker, Head of Richmond's Data Management service completed the 2006 London Marathon in 4 hours and 24 minutes - his best time in 3 years.Richmond Pharmacology Ltd sponsored Adam £500 to complete the run and in total he has raised £3,000 for Bliss, the premature baby charity.Training for this year's run started in December 2005, although he did have his setbacks."In February I was admitted to hospital and was put on a drip for 2 days with a mystery illness this happened just 6 weeks before the marathon. Fortunately I made a rapid recovery and was able to resume training."Next year he aims to complete the course in under 4 hours!"By mile 20 I had a massive burst of energy and pushed on for the last 6 miles - sprinting to the finishing line!"The charity Bliss is dedicated to caring for premature babies: "This is the third consecutive year I have run to support Bliss and over the 3 years I have raised more than £10,000 for the charity. My daughter Amelie Grace was born 6 weeks prematurely and was in intensive care at the Sussex County Hospital, Brighton for 4 weeks. I am very grateful that Amelie was able to make a full recovery. I will continue to raise money for Bliss to help other families who find themselves in the same position"To find out more about Bliss visit: www.bliss.org.ukTo sponsor Adam, visit: www.justgiving.com/adamwalker_londonmarathon2006.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more